Latest News

Why Myopia Increases the Relative risk of Open-angle Glaucoma

Monica Jong, PhD, BOptom Assistant Professor, DOVS, University of Canberra Executive Director, International Myopia Institute, BHVI Sydney Collaborating Scientist, BHVI Sydney Visiting Fellow, SOVS, UNSW Sydney Myopia and high myopia are estimated to affect 50 percent (5 billion) and 10 percent (938 million) of the worldwide population by 2050, and consequently, we will also see a

Read More »

Calling for Awareness of Vision-threatening Complications Associated with Myopia

Xiao (Nicole) Liu, MOptom, PhD Candidate BHVI It is well recognized that having myopia increases the risk for developing a number of sight-threatening conditions, namely myopic macular degeneration (MMD), retinal detachment (RD), cataract and open angle glaucoma (OAG). To illustrate the pressing need for a holistic myopia management approach, Haarman et al. (2020) conducted a systematic

Read More »

Our Purpose

We fulfil unmet needs in the ophthalmic space by innovating commercially relevant technologies through to feasibility.

We generate ideas.  We push the scientific envelope.  We solve problems.  We translate and communicate our knowledge. We look forward.

Our Values


We focus exclusively on research, development and ophthalmic sector support.


We lead with industry, solving problems and creating technology. We bring new ideas to markets.


We focus on meeting unmet needs. We trial, test, learn, share and adapt. 


We cannot achieve without each other; our team, our partners and our customers.

Learn myopia management with BHVI.

So the next generation can keep

A myopia patient is a lifelong patient.

BHVI’s world leading Myopia Education Program brings you the latest research, clinical procedures, and business expertise.

Copyright © Brien Holden Vision Institute (ABN 49 081 303 282) Brien Holden Vision Institute Foundation (ABN 86 081 872 586). All Rights Reserved.

Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens

SYDNEY, Australia and LAVAL, Quebec, Oct. 15, 2020 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, along with BHVI, an Australian not-for-profit organization with an international focus on vision research, announced today that an affiliate of Bausch Health has acquired an exclusive license for a myopia control contact lens design developed by BHVI. Bausch + Lomb will pair BHVI’s novel contact lens design with its leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children.

Our site uses cookies. By continuing to use this website, you agree to their use. For more details, please check our Privacy Policy.